32
https://pubmed.ncbi.nlm.nih.gov/38115358
The meta-analysis of four randomized clinical trials found that Faricimab offers non-inferior or better central subfoveal thickness improvement than other anti-VEGF therapies for age-related macular degeneration and diabetic macular edema, with extended dosing intervals.